|
▶ Video account attention cross-border navigation It is learned that the COVID-19 situation in the United States is still severe, with 331,250 new confirmed cases on January 17. Under the ravages of the Omicron virus, the United States still faces multiple challenges. With the explosive growth in the number of confirmed cases, the demand for epidemic products in the United States is also increasing day by day. ▲ The picture comes from the Internet Nucleic acid testing kits are in serious shortage in the United States By the end of 2021, Omicron had landed throughout the United States, and the scale of testing in the United States increased fourfold. Entering 2022, the United States once again faced a series of crises brought about by the raging virus, and nucleic acid testing kits for the new coronavirus were out of stock, and in many places, "one box is hard to come by." It is learned that due to the wide coverage of nucleic acid testing abroad and the long appointment time, purchasing rapid testing kits that can be used at home has become the choice of many Americans. However, in recent days, nucleic acid test kits are either sold out or have empty shelves in major retail stores and pharmacies in the United States. When searching for nucleic acid test kits on Amazon, the results are all "sold out" and "unclear arrival time." Under this circumstance, the US government announced the purchase of testing kits. As early as January 4, the Biden administration stated that it was about to sign a contract to purchase 500 million rapid testing kits for the new coronavirus. Recently, there has been new progress in this procurement plan. The US government stated that as part of the distribution plan of the first 500 million free test kits, American citizens can order free new crown test kits online starting from January 19, 2022. US President Biden said that he has instructed the US government to purchase an additional 500 million test kits on top of the previous 500 million test kits , with no cap on the total purchase quantity. It is reported that the US government has completed the purchase contract for 420 million test kits in the first order. The first order of 500 million is expected to cost US$4 billion (average unit price of US$8). The US government may award more contracts in the coming weeks. The purchase of 1 billion boxes of COVID-19 testing reagents reflects the huge demand for epidemic supplies in the United States . Currently, the main supplier of COVID-19 rapid self-test kits in the world is China. This phenomenon has also contributed to the performance of related domestic medical companies. As one of the domestic companies authorized by the U.S. FDA, iHealth has also successfully signed a tens of billions of orders from the United States with its popular products. Jiuan Medical Signs Orders of Over 10 Billion Yuan It is understood that Tianjin Jiuan Medical was established in 1995. It is a listed company focusing on the research and development and production of health electronic products and smart hardware. Its main products cover blood pressure, blood sugar, body temperature, body fat/weight, blood oxygen, electrocardiogram and other fields. Recently, Jiuan Medical has become the "new favorite" of many stock investors. According to Huanqiu.com, the market value of Jiuan Medical has soared from less than 3 billion to more than 30 billion in just over two months. In the past two months, it has achieved 27 daily limits, and its stock price has been rising all the way. It has received 3 letters of concern and 1 supervision letter from the Shenzhen Stock Exchange, and is known as the "big demon stock across the New Year." All of this originated from an emergency use authorization (EUA) from the U.S. Food and Drug Administration. On November 8, 2021, iHealth announced that its U.S. subsidiary's COVID-19 antigen home self-test OTC kit has obtained emergency use authorization (EUA) from the U.S. Food and Drug Administration. ▲ The picture comes from Jiuan Medical’s official website iHealth said that the passing of the emergency use authorization (EUA) for this testing product has enriched the company's product line, which is an important breakthrough for the company in the IVD field. It has enhanced the company's core competitiveness and market expansion capabilities, and is expected to bring relevant sales revenue to the company in the future. At the same time, just last week, iHealth announced that it had received a large order for home COVID-19 testing from the United States. On January 13, iHealth announced that its subsidiary had received orders for iHealth COVID-19 Antigen Home Self-Test OTC Kits from New York State and Massachusetts, with the total contract price and tax being US$185 million (approximately RMB 1.179 billion) and US$148 million (approximately RMB 944 million) , respectively . On January 14, iHealth issued another announcement stating that its US subsidiary had received a procurement contract from the US ACC (US Army Contracting Command). The total contract price and tax was US$1.275 billion, or approximately RMB 8.1 billion. ▲ The picture comes from Jiuan Medical’s announcement It is worth mentioning that in the above two contracts, the order amounts have exceeded 50% of iHealth’s audited main business revenue in 2020 (RMB 1.004 billion) , and the fulfillment of the contracts will have a positive impact on its operating income and operating profit in 2022. So far, the two orders signed by Jiuan Medical have exceeded RMB 10 billion, which is obviously a proud achievement for a listed company. However, it is not easy to complete such a super large order. Jiuan Medical: Billions of Orders Are at Risk On January 15, 2022, iHealth Medical announced again that it has obtained the US FDA EUA authorization for the iHealth COVID-19 Antigen Rapid Test Pro POC Professional Edition Kit. ▲ The picture comes from Jiuan Medical’s announcement With the release of one blockbuster piece of news after another, the share price of Jiuan Medical has soared, making many stockholders excited. However, the higher the position, the more you should be prepared for danger. It is learned that on January 17, iHealth issued an "Announcement on Abnormal Stock Trading Fluctuations and Risk Warnings", stating that iHealth's stock has experienced large fluctuations recently, and investors are advised to pay attention to investment risks. ▲ The picture comes from Jiuan Medical’s announcement The announcement stated that investors should note that the monthly performance of the test kit product does not represent the full-year performance, and the historical performance of the product does not represent future performance. The company believes it is necessary to once again issue the following risk warning: 1. Risk of uncertainty in the development of the epidemic in the United States 2. Uncertainty risks in market competition 3. Reasonableness risk of valuation model 4. Information reliability risk 5. Risk of exchange rate fluctuations 6. Logistics and transportation risks In addition, it should be pointed out that the U.S. government has the right to terminate the contract at any time due to its own reasons. The above means that the U.S. government can request to stop the execution of the contract without any reason and cancel subsequent purchases. The seller must bear the corresponding risks and possible losses. Many people outside the company are envious of the recent popularity of Jiuan Medical, but the tens of billions of orders did not come out of nowhere. I hope that in 2022, every seller can achieve the goal of big sales through hard work!
|
